U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Fallopian Tube Carcinoma

MedGen UID:
1720192
•Concept ID:
C5238359
•
Neoplastic Process

Definition

Fallopian tube carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced Fallopian Tube Carcinoma

Professional guidelines

PubMed

Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline.
Vanderpuye VD, Clemenceau JRV, Temin S, Aziz Z, Burke WM, Cevallos NL, Chuang LT, Colgan TJ, Del Carmen MG, Fujiwara K, Kohn EC, Gonzáles Nogales JE, Konney TO, Mukhopadhyay A, Paudel BD, Tóth I, Wilailak S, Ghebre RG
JCO Glob Oncol 2021 Jun;7:1032-1066. doi: 10.1200/GO.21.00085. PMID: 34185571Free PMC Article
Frontline Maintenance Treatment for Ovarian Cancer.
Elyashiv O, Wong YNS, Ledermann JA
Curr Oncol Rep 2021 Jun 14;23(8):97. doi: 10.1007/s11912-021-01088-w. PMID: 34125335Free PMC Article
Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
Webber K, Friedlander M
Best Pract Res Clin Obstet Gynaecol 2017 May;41:126-138. Epub 2016 Nov 23 doi: 10.1016/j.bpobgyn.2016.11.004. PMID: 28027849

Recent clinical studies

Etiology

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y
Int J Clin Oncol 2022 Dec;27(12):1874-1880. Epub 2022 Oct 10 doi: 10.1007/s10147-022-02246-1. PMID: 36214925
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol 2021 Nov;16(6):847-856. Epub 2021 Oct 8 doi: 10.1007/s11523-021-00842-1. PMID: 34623572
Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience.
Chang CH, Kuo HL, Chen TC, Weng CS, Lim L, Huang WC, Chang CL, Su TH, Wang KG, Wang KL, Yang YC, Chen JR
Int J Environ Res Public Health 2020 May 18;17(10) doi: 10.3390/ijerph17103523. PMID: 32443497Free PMC Article

Diagnosis

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.
Pereira M, Glogova A, Haagsma J, Stewart J, Shepherd TG, Petrik J
J Ovarian Res 2023 Nov 20;16(1):218. doi: 10.1186/s13048-023-01307-x. PMID: 37986175Free PMC Article
Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Taylor SE, Chu T, Elvin JA, Edwards RP, Zorn KK
Gynecol Oncol 2020 Jan;156(1):32-37. Epub 2019 Nov 15 doi: 10.1016/j.ygyno.2019.10.029. PMID: 31739991
Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
Webber K, Friedlander M
Best Pract Res Clin Obstet Gynaecol 2017 May;41:126-138. Epub 2016 Nov 23 doi: 10.1016/j.bpobgyn.2016.11.004. PMID: 28027849
Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.
Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, Bracchi C, Tomao F, Di Donato V, De Felice F, Monti M, Muzii L, Benedetti Panici P
Chemotherapy 2017;62(2):111-120. Epub 2016 Oct 29 doi: 10.1159/000448942. PMID: 27794568

Therapy

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.
Pereira M, Glogova A, Haagsma J, Stewart J, Shepherd TG, Petrik J
J Ovarian Res 2023 Nov 20;16(1):218. doi: 10.1186/s13048-023-01307-x. PMID: 37986175Free PMC Article
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol 2021 Nov;16(6):847-856. Epub 2021 Oct 8 doi: 10.1007/s11523-021-00842-1. PMID: 34623572
Frontline Maintenance Treatment for Ovarian Cancer.
Elyashiv O, Wong YNS, Ledermann JA
Curr Oncol Rep 2021 Jun 14;23(8):97. doi: 10.1007/s11912-021-01088-w. PMID: 34125335Free PMC Article
Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
Webber K, Friedlander M
Best Pract Res Clin Obstet Gynaecol 2017 May;41:126-138. Epub 2016 Nov 23 doi: 10.1016/j.bpobgyn.2016.11.004. PMID: 28027849

Prognosis

Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
Hendrikse CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, Oosterkamp F, Theelen PMM, Lok CAR, de Hullu JA, Smedts HPM, Vos MC, Pijlman BM, Kooreman LFS, Bulten J, Lentjes-Beer MHFM, Bosch SL, van de Stolpe A, Lambrechts S, Bekkers RLM, Piek JMJ
Cancer 2023 May 1;129(9):1361-1371. Epub 2023 Mar 3 doi: 10.1002/cncr.34661. PMID: 36867576
A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.
Sinukumar S, Rajan F, Mehta S, Damodaran D, Zaveri S, Kammar P, Bhatt A
Eur J Surg Oncol 2021 Jan;47(1):75-81. Epub 2019 Feb 23 doi: 10.1016/j.ejso.2019.02.031. PMID: 30857879
Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.
Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, Bracchi C, Tomao F, Di Donato V, De Felice F, Monti M, Muzii L, Benedetti Panici P
Chemotherapy 2017;62(2):111-120. Epub 2016 Oct 29 doi: 10.1159/000448942. PMID: 27794568
Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T, Kato K, Taniguchi T, Abe A, Nomura H, Yamamoto A, Matoda M, Okamoto S, Kondo E, Omatsu K, Kawamata Y, Takeshima N
Int J Gynecol Cancer 2014 Jul;24(6):991-6. doi: 10.1097/IGC.0000000000000142. PMID: 24905612
Non-primary cervical adenocarcinomas.
Mulvany NJ, Nirenberg A, Oster AG
Pathology 1996 Nov;28(4):293-7. doi: 10.1080/00313029600169214. PMID: 9007944

Clinical prediction guides

Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
Hendrikse CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, Oosterkamp F, Theelen PMM, Lok CAR, de Hullu JA, Smedts HPM, Vos MC, Pijlman BM, Kooreman LFS, Bulten J, Lentjes-Beer MHFM, Bosch SL, van de Stolpe A, Lambrechts S, Bekkers RLM, Piek JMJ
Cancer 2023 May 1;129(9):1361-1371. Epub 2023 Mar 3 doi: 10.1002/cncr.34661. PMID: 36867576
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y
Int J Clin Oncol 2022 Dec;27(12):1874-1880. Epub 2022 Oct 10 doi: 10.1007/s10147-022-02246-1. PMID: 36214925
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.
Sinukumar S, Rajan F, Mehta S, Damodaran D, Zaveri S, Kammar P, Bhatt A
Eur J Surg Oncol 2021 Jan;47(1):75-81. Epub 2019 Feb 23 doi: 10.1016/j.ejso.2019.02.031. PMID: 30857879
Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T, Kato K, Taniguchi T, Abe A, Nomura H, Yamamoto A, Matoda M, Okamoto S, Kondo E, Omatsu K, Kawamata Y, Takeshima N
Int J Gynecol Cancer 2014 Jul;24(6):991-6. doi: 10.1097/IGC.0000000000000142. PMID: 24905612

Recent systematic reviews

Extra-abdominal ovarian cancer presenting with breast metastases at diagnosis: Case report and literature review.
Ferrari F, Ficarelli S, Forte S, Valenti G, Ardighieri L, Sartori E, Odicino F
Eur J Obstet Gynecol Reprod Biol 2020 Dec;255:211-221. Epub 2020 Oct 12 doi: 10.1016/j.ejogrb.2020.10.004. PMID: 33152565
Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):463-471. Epub 2018 Apr 22 doi: 10.1016/j.clon.2018.03.036. PMID: 29691126

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...